Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Cash from Financing Activities (2023 - 2025)

Historic Cash from Financing Activities for Artiva Biotherapeutics (ARTV) over the last 3 years, with Q3 2025 value amounting to -$37000.0.

  • Artiva Biotherapeutics' Cash from Financing Activities fell 10002.26% to -$37000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $100000.0, marking a year-over-year change of. This contributed to the annual value of $162.2 million for FY2024, which is 56510.6% up from last year.
  • Per Artiva Biotherapeutics' latest filing, its Cash from Financing Activities stood at -$37000.0 for Q3 2025, which was down 10002.26% from -$72000.0 recorded in Q2 2025.
  • In the past 5 years, Artiva Biotherapeutics' Cash from Financing Activities ranged from a high of $163.9 million in Q3 2024 and a low of -$72000.0 during Q2 2025
  • Over the past 3 years, Artiva Biotherapeutics' median Cash from Financing Activities value was $239000.0 (recorded in 2025), while the average stood at $26.9 million.
  • Data for Artiva Biotherapeutics' Cash from Financing Activities shows a peak YoY increase of 59938.12% (in 2024) and a maximum YoY decrease of 10311.85% (in 2024) over the last 5 years.
  • Quarter analysis of 3 years shows Artiva Biotherapeutics' Cash from Financing Activities stood at $962000.0 in 2023, then crashed by 103.12% to -$30000.0 in 2024, then dropped by 23.33% to -$37000.0 in 2025.
  • Its Cash from Financing Activities was -$37000.0 in Q3 2025, compared to -$72000.0 in Q2 2025 and $239000.0 in Q1 2025.